Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network (2023-12377081)

November 16, 2026 updated by: Istituto Giannina Gaslini

Potenziare la Gestione Clinica Delle CMF Attraverso Una Rete Nazionale Pediatrica e Dell'Adulto Basata su Dati Biologici e Genetici / Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network

A non-profit, translational, prospective and retrospective study.

Patients will be enrolled according to the procedures described in the protocol, and samples will be processed and analyzed as specified in the protocol.

Since constitutional bone marrow failure syndromes (CMF) are rare genetic disorders characterized by a variable and incompletely defined clinical phenotype, a partially unknown genetic etiology, and pathogenetic mechanisms that are only partly understood, the investigators hypothesize that a number of patients currently diagnosed with idiopathic acquired aplastic anemia (AAA) or idiopathic single-lineage/multilineage bone marrow failure (BMF) may have been misdiagnosed and may actually have an underlying CMF.

Therefore, the investigators' primary objective is to identify CMF underlying BMF and vice versa, by defining well-characterized patient cohorts based on clinical and family history, clinical manifestations, and immunological findings; identifying disease-specific parameters and biomarkers; and providing disease-specific guidelines to facilitate early diagnosis and, consequently, enable timely and appropriate treatment.

In this context, the use of appropriate artificial intelligence (AI) tools is likely to improve the diagnostic accuracy of this approach.

Study Overview

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Avellino, Italy
        • Recruiting
        • AORN San Giuseppe Moscati Hematology and bone marrow Transplant Unit
        • Contact:
      • Genova, Italy
      • Naples, Italy
        • Recruiting
        • Azienza Ospedaliera di Rilievo Nazionale Santobono Pausilipon Dipartimento di oncologia, ematologia e terapie cellulari
        • Contact:
      • Verona, Italy
        • Not yet recruiting
        • Università degli Studi di Verona Department of Engineering for Innovation Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 weeks to 99 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)

Description

Inclusion Criteria:

  • Patients diagnosed with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH).
  • Signed informed consent and/or assent obtained from the participant and/or their parents or legal guardians, as applicable.

Exclusion Criteria:

  • Absence of signed informed consent and/or assent from the participant and/or their parents or legal guardians

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Fanconi anemia (FA)

Fanconi anemia (FA)

Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)

Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)

Congenital neutropenia (CN)

Congenital neutropenia (CN)

Primary immune regulatory disorders (PIRD)

Primary immune regulatory disorders (PIRD)

Congenital amegakaryocytic thrombocytopenia (CAMT)

Congenital amegakaryocytic thrombocytopenia (CAMT)

Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)

Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Early Diagnosis and Molecular Characterization of CMF and AAA
Time Frame: Within the 24-month project period

To improve the early diagnosis of constitutional bone marrow failure syndromes (CMF) and acquired aplastic anemia (AAA) through the integration of clinical, laboratory, immunological, and genetic data. At least 50 newly enrolled patients will be evaluated prospectively over the first 21 months, alongside approximately 200 previously referred patients analyzed retrospectively using artificial intelligence (AI). The diagnostic work-up will include the implementation of additional tests, such as telomere length assessment by flow-FISH, serum thrombopoietin measurement, and immunophenotyping by flow cytometry. Whole-genome sequencing and functional studies will be used to identify disease-causing variants, copy number variations (CNVs), and clarify variants of uncertain significance (VUS). Early and accurate diagnosis will support appropriate targeted treatment, genetic counseling, surveillance for bone marrow failure and malignancies, and identification of suitable related donors.

Within the 24-month project period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 29, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

February 28, 2027

Study Registration Dates

First Submitted

October 9, 2026

First Submitted That Met QC Criteria

October 9, 2026

First Posted (Actual)

October 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe